Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619900 | 0.91 | ADORA3 (0.64) | ADORA3ADORA2AADORA2BADORA1IMPDH2 | |
| Xanthosine SCHEMBL6676995 | 0.86 | LMNA (0.65) | ADORA3ADORA2AADORA2BADORA1 | |
| Xanthosine SCHEMBL8665102 | 0.86 | LMNA (0.65) | ADORA3ADORA2AADORA2BADORA1 | |
| Xanthosine SCHEMBL188120 | 0.86 | LMNA (0.65) | ADORA3ADORA2AADORA2BADORA1 | |
| Xanthosine SCHEMBL11523732 | 0.86 | LMNA (0.65) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL780585 | 0.86 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL41365 | 0.86 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1 | |
| Xanthosine SCHEMBL5352244 | 0.85 | LMNA (0.63) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL188740 | 0.84 | CA5A (0.68) | ADORA1IMPDH2IMPDH1 | |
| SCHEMBL11426071 | 0.84 | CA1 (0.58) | ADORA3ADORA2AADORA2BADORA1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024099575-A1 | ARTIFICIAL NUCLEIC ACIDS FOR SITE-DIRECTED EDITING OF A TARGET RNA | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2024-05-16 | — | — | WO | disclosed |
| EP-1985702-A2 | CPG-like nucleic acids and methods of use thereof | Coley Pharmaceuticals GmbH (DE) | 2008-10-29 | — | — | EP | disclosed |
| US-20030207307-A1 | Determining biochemical markers of progression and therapy monitoring and specification, therapeutic lead molecules, and target biochemical systems applied to stroke | ESA, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003089898-A2 | DETERMINING BIOCHEMICAL MARKERS OF PROGRESSION AND THERAPY MONITORING AND SPECIFICATION, THERAPEUTIC LEAD MOLECULES, AND TARGET BIOCHEMICAL SYSTEMS APPLIED TO STROKE | ESA, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207307-A1 | Determining biochemical markers of progression and therapy monitoring and specification, therapeutic lead molecules, and target biochemical systems applied to stroke | SHMT2, FABP7, FABP3 | ADORA3 4135/4885ADORA2A 4094/4885ADORA2B 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.